[Cytomegalovirus infection in patients after lung transplantation].
Cerrina
J
J
Le Roy Ladurie
F
F
D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D017245:Foscarnet; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance; D015994:Incidence; D016040:Lung Transplantation / Q000009:adverse effects*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D015995:Prevalence; D014765:Viral Vaccines / Q000008:administration & dosage
D000998:Antiviral Agents; D014765:Viral Vaccines; D017245:Foscarnet; D010746:Phosphonoacetic Acid; D015774:Ganciclovir; D000212:Acyclovir
Infection à cytomégalovirus chez les transplantés pulmonaires.